What does AnGes, Inc. do?

AnGes, Inc. (AMGXF) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.

What is AMGXF's market cap?

AnGes, Inc. (AMGXF) has a market capitalization of approximately $142.5 million, as of August 27, 2026, based on the most recent share price and shares outstanding.

Does AMGXF pay a dividend?

No — AnGes, Inc. (AMGXF) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.

AnGes, Inc. (AMGXF) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.

AMGXF

AnGes, Inc.

OTC·Biotechnology · Healthcare

$0.36$0.00+0.00%

Market cap$142.50M·Aug 27 8:00 PM UTC

Price Chart

$0.36+$0.00 (+0.00%)today

−94.47%CAGR −43.99%

Select date range

FromTo

Jul 3, 2017Aug 28, 2021 → Aug 28, 2026· 5.0 yrsAug 28, 2026

Key Metrics

AMGXF does not currently pay a dividend.

EarningsEarnings Tab

EPS (FWD)—

P/E Ratio (FWD)—

EPS Growth (1Y)—

EPS Growth (3Y)—

EPS Growth (5Y)—

Next Earnings DateNov 6

Last Report DateAug 14

Reported vs Estimate−$0.03

Earnings Surprise—

FinancialsFinancials Tab

Revenue¥964.52M

Net Income−¥3.88B

Net Margin−402.0%

Operating Cash Flow¥0.00

Capital Expenditures¥0.00

Free Cash Flow¥0.00

Return on Equity−1,898.8%

Return on Invested Capital−170.9%

Net Debt¥423.98M

Value Graph

PRO

See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.

Click below to see what's inside, then upgrade to unlock for AMGXF and 80,000+ other tickers.

EPS · Price vs. Fair Value Price Fair

Income Statement Flow

PRO

See exactly how AMGXF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.

The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for AMGXF and 80,000+ other tickers.

About AnGes, Inc.

AnGes, Inc., a biopharmaceutical firm established in 1999 and headquartered in Ibaraki, Japan, specializes in the research and advancement of gene-based medical solutions. The company's flagship product is Hepatocyte Growth Factor (HGF) Plasmid, a pioneering gene therapy developed to address critical limb ischemia, a severe condition characterized by impaired blood circulation in the legs. Beyond its lead therapy, AnGes is progressing a diverse portfolio of treatments. This includes NF-kB Decoy Oligonucleotide, a nucleic acid medicine designed to mitigate inflammation, which is being…

CEO: Ei Yamada
Sector: Healthcare
Industry: Biotechnology
Exchange: OTC
Employees: 56
Website: www.anges.co.jp

Peers

Peers Tab

ADPT

Adaptive Biotechnologies Corporation

Cap

$4.0B

CASBF

CanSino Biologics Inc.

Cap

$1.6B

FBIO

Fortress Biotech, Inc.

Cap

$93.2M

Latest News

News Tab

No recent news available.

Frequently Asked Questions About AMGXF

What does AnGes, Inc. do?: AnGes, Inc. (AMGXF) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.
What is AMGXF's market cap?: AnGes, Inc. (AMGXF) has a market capitalization of approximately $142.5 million, as of August 27, 2026, based on the most recent share price and shares outstanding.
Does AMGXF pay a dividend?: No — AnGes, Inc. (AMGXF) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.
Is AMGXF profitable?: AnGes, Inc. (AMGXF) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.